To send content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about sending content to .
To send content items to your Kindle, first ensure firstname.lastname@example.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about sending to your Kindle.
Note you can select to send to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
This chapter reviews the mechanism of action of cladribine, summarizes data from clinical trials in patients with multiple sclerosis (MS), and provides guidance on the management of these patients in clinical practice. The study of parenteral cladribine showed encouraging results, which lead to the development of an oral tablet formulation. Cladribine is rapidly absorbed with Cmax within 30- 50 minutes after oral administration. CLARITY, a 96-week, placebo-controlled Phase 3 study of cladribine tablets as an annual short-course oral monotherapy in RRMS, was recently completed and the principal results published. Benefit of doses of cladribine over placebo was demonstrated for a variety of clinical and imaging end-points. The most common adverse events in the patients were lymphopenia, headache, nasopharyngitis, and upper respiratory tract infections (URTI). The outcomes observed during the CLARITY study were associated with a reduced consumption of health care resources and a decreased need for medical and societal support.
This chapter lists the factors that differentiate pharmacogenomics from conventional biomarker research on a strategic, operational, and technical level. The "-omics" technologies and conventional methods are mutually complementary approaches in the search for biomarkers. The genetic component of multiple sclerosis (MS) risk has been the focus of study for a long time, and beyond the classic association with the MHC locus, seven genome-wide association studies (GWAS) reported in recent years have helped identify other candidate genes, such as the IL-7 and IL-2 receptors. Compared with DNA- and RNA-based analyses, proteomics and metabolomics are less advanced techniques. The requirements for establishing a comprehensive and integrated matrix of genotype/phenotype interaction are: development of technologies for proteomics and metabolomics to the same level as genotyping and trancriptomics, development of bioinformatic tools, and development of longitudinally studied cohorts characterized using standardized, high-quality clinical and paraclinical methods.
Email your librarian or administrator to recommend adding this to your organisation's collection.